Hereditary Pheochromocytoma Assessment of Tumour Immunologies

Summary

In this study, the investigators are examining the role of the immune system in pheochromocytoma and paraganglioma. The investigators aim to examine the differences in the immune system between people who have these tumors with and without a hereditary predisposition. The investigators also want to see how the immune system changes during the development of the tumor in people with a hereditary predisposition. Finally, the investigators will compare the data with a control group of people without these tumors. Ultimately, the investigators hope that the results will contribute to the discovery of new immune system-targeted medications for pheochromocytoma and paraganglioma.

Eligibility

Inclusion Criteria:

Part I:

* Newly diagnosed patients with PPGL or newly diagnosed patients with (metastatic) PPGL recurrence.
* OR patients with mutations which predispose for the development of PPGL.
* Aged \> 18 years.

Part II:

* Confirmed PPGL on pathology.
* Aged \> 18 years.

Exclusion Criteria:

* Unable to provide informed consent.
* Active inflammatory or infectious comorbidities.
* Other malignancies which are under active treatment (except for basal cell carcinoma, other in situ carcinomas).
* Using medication interfering with the immune system
* Pregnancy or breastfeeding
* A self-reported alcohol consumption of \>21 units per week

Conditions3

Browse More Trials